Basic Sciences of Medicine

Basic Sciences of Medicine is a peer reviewed international basic medical sciences journal, which is aimed to promote research and information in basic medical sciences. It can improve health, health care and health education, internationally by elevating the quality of medical care, disease prevention, and research.

Dimitrios Farmakis

Editorial Board Member of Basic Sciences of Medicine

Lecturer, First Dept. of Medicine, Athens University Medical School, Greece

Research Areas

Cardiology, Hemoglobinopathies, Heart Failure

Education

2003Ph.DUniversity of Athens Medical School
1996M.D.University of Athens Medical School

Experience

2010-presentLecturer, University of Athens Medical School, Athens, Greece
2011-presentLecturer, University of Athens School of Pharmacy, Athens, Greece
2010-presentAttending Cardiologist,University of Athens Medical School, Laiko University Hospital, Athens, Greece
2008-presentMedical Advisor, G.A.P. Pharmaceuticals S.A., Athens, Greece
2004-2008Fellow in Cardiology, 2nd Dept. of Cardiology, University of Athens Medical School, Attikon University Hospital, Athens, Greece
2002-2004Clinical Research Fellow, 2nd Dept of Medical Oncology, Metaxas Cancer Hospital, Piraeus, Greece
1999-2001Hellenic Air Force Physician
1998-1999Primary Care Physician, Sifnos Public Surgery, Cyclades, Greece
1995-1998Clinical Research Fellow, University of Athens Medical School, Laiko University Hospital, and Medical Physics Lab, University of Athens Medical School, Athens, Greece

Academic Achievement

Hellenic Society of Cardiology, 1-year scholarship for training in UK on molecular cardiology, magnetic resonance imaging and molecular imaging in heart failure and cardiomyopathies
American Heart Association, "Effects of Recombinant Human Erythropoietin on Left Ventricular Diastolic and Systolic Function, and Plasma Biomarkers of Neurohormonal Activation in Patients with Chronic Heart Failure and Anemia", American Heart Association
Hellenic Society of Heart Failure Study and Research (EMEKA): "Effect of human recombinant erythropeotin on cardiac function and neurohormonal activation in patients with chronic heart failure and anemia", 7th Panhellenic Heart Failure Congress, Athens, F
Hellenic Society of Heart Failure Study and Research (EMEKA): "Serum prolactin levels are increased in patients with chronic heart failure and depression and are associated with activation of immune mechanisms", 11th Panhellenic Heart Failure Congress. At
Society of Hellenic Medical Oncologists (ΕΟΠΕ): "Comparison of docetaxel monotherapy and docetaxel-irinotecan combination as second-line therapy in advanced non-small cell lung cancer: a randomized phase II trial", 12th Panhellenic Congress of Clinical On

Membership

Piraeus Medical Association (1997-1998 and 1999-2004)
Cyclades Medical Association (1998-1999)
Athens Medical Association (2004-today)
Hellenic Society of Lipidiology and Atherosclerosis (2004-today)
Hellenic Society of Cardiology (2010-today)

Publications: Journals

[1]  Aessopos Α, Farmakis D, Karagiorga M, Rombos Ι, Loucopoulos D. Pseudoxanthoma Elasticum Lesions and Cardiac Complications as Contributing Factors for Strokes in β-Thalassemia Patients. Stroke 1997;28:2421-2424.
[2]  Aessopos A, Karabatsos F, Farmakis D, Katsantoni A, Hatziliami A, Youssef J, Karagiorga M. Pregnancy in well-treated β-thalassemic patients: Outcome for mothers and newborns. Am J Obstet Gynecol 1999;180:360-365.
[3]  Aessopos Α, Farmakis D, Tassiopoulos T, Taktikou H, Perakis A, Stamatelos G, Loucopoulos D. Doppler-determined tricuspid pressure gradient in individuals with normal pulmonary function and tricuspid regurgitation. J Am Soc Echocardiogr 2000;13:645-649.
[4]  Aessopos A, Farmakis D, Karagiorga M, Voskaridou E, Hatziliami A, Joussef J, Rombos J, Loukopoulos D. Cardiac involvement in thalassemia intermedia: A multicenter study. Blood 2001;97:3411-3416.
[5]  Aessopos A, Tsironi M, Vassiliadis I, Farmakis D, Fountos A, Voskaridou E, Perakis A, Defteraios S, Loutradi A, Loukopoulos D. Exercise-induced myocardial perfusion abnormalities in sickle β-thalassemia: Tc-99m tetrofosmin gated SPECT imaging study. Am J Med 2001;111:355-360.
[6]  Aessopos A, Farmakis D, Loukopoulos D. Elastic tissue abnormalities resembling pseudoxanthoma elasticum in β thalassemia and the sickling syndromes. Blood 2002;99:30-35.
[7]  Deftereos S, Lambrinoudakis C, Andriopoulos P, Farmakis D, Aessopos A. A Java-based Electronic Healthcare Record Software for beta-Thalassaemia. J Med Internet Res 2001;3:e33 (URL: http://www.jmir.org/2001/4/e33/).
[8]  Aessopos A, Politou M, Farmakis D, Sideris P, Grapsa A, Andreopoulos A, Kalahanis N, Karagiorga M. Staphylococcus aureus abscess of the spleen in a β thalassemia patient. Scand J Infect Dis 2002;34:466-468.
[9]  Aessopos A, Farmakis D, Loukopoulos D. Elastic tissue abnormalities in inherited hemolytic syndromes. Eur J Clin Invest 2002;32:640-642.
[10]  Aessopos Α, Grapsa Α, Sideris P, Farmakis D, Politou M, Paikos S, Aroni K. Oral paraneoplastic pemphigus associated with renal malignancy: A case report. Acta Dermato-Venereol 2003;83:72-73.
[11]  Farmakis D, Moyssakis I, Perakis A, Rombos Y, Deftereos S, Giakoumis A, Polymeropoulos E, Aessopos A. Unstable angina associated with coronary arterial calcification in a thalassemia intermedia patient with a pseudoxanthoma elasticum-like syndrome. Eur J Haematol 2003;70:64-66.
[12]  Farmakis D, Giakoumis A, Polymeropoulos E, Aessopos A. Pathogenetic aspects of immune deficiency in thalassemia. Med Sci Monit 2003; 9:RA 19-22.
[13]  Pectasides D, Pectasides M, Farmakis D, Bountouroglou N, Nikolaou M, Koumpou M, Mylonakis N, Kosmas C. Oxaliplatin plus high dose leucovorin and 5-fluorouracil as salvage treatment in advanced breast cancer. Phase II study. Ann Oncol 2003;14:537-42.
[14]  Pectasides D, Mylonakis N, Farmakis D, Nikolaou M, Koumpou M, Katselis I, Gaglia A, Kostopoulou V, Karabelis A, Kosmas C. Irinotecan and gemcitabine in patients with advanced non-small cell lung cancer, previously treated with cisplatin-based chemotherapy. A Phase II study. Anticancer Res 2003;23:4205-11.
[15]  Pectasides D, Skarlos D, Dimopoulos A, Farmakis D, Pectasides M, Fountzilas G, Aravantinos G. Two-cycles of carbopltin-based adjuvant chemotherapy for high-risk clinical stage I and stage IM non-seminomatous germ cell tumours of the testis: A HeCOG Trial. Anticancer Res 2003;23:4239-44.
[16]  Pectasides D, Pectasides M, Farmakis D, Nikolaou M, Koumpou M, Kostopoulou V, Mylonakis N. Testicular function in patients with testicular cancer treated with bleomycin-etoposide-carboplatin (BEC90) combination chemotherapy. Eur Urol 2004;45:187-93.
[17]  Pectasides D, Pectasides M, Farmakis D, Aravantinos G, Nikolaou M, Koumpou M, Gaglia A, Kostopoulou V, Mylonakis N, Skarlos D. Gemcitabine and Oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors. A Phase II study. Ann Oncol 2004;15: 493-7.
[18]  Farmakis D, Deftereos S, Giakoumis A, Polymeropoulos E, Aessopos A. Rupture of chordae tendineae in patients with β-thalassemia. Eur J Haematol 2004;72:296-8.
[19]  Aessopos A, Farmakis D. Comments on the European guidelines on cardiovascular disease prevention. Eur Heart J 2004;25:619.
[20]  Pectasides D, Pectasides M, Farmakis D, Aravantinos G, Nikolaou M, Koumpou M, Gaglia A, Kostopoulou V, Mylonakis N, Economopoulos T, Raptis S. Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor patients. A phase II study. Eur Urol 2004;46:216-21.
[21]  Pectasides D, Pectasides M, Farmakis D, Gaglia A, Koumarianou A, Nikolaou M, Koumpou M, Kountourakis P, Papaxoinis G, Mitrou P, Economopoulos T, Raptis SA. Oxaliplatin plus high dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant, taxane-pretreated: ovarian cancer. A phase II study. Gynecol Oncol 2004;95:165-72.
[22]  Deftereos S, Farmakis D, Papadogianni A, Besleme B, Diamanti-Kandarakis E, Polymeropoylos E, Georgonikou D, Aessopos A. Waldenstrom's macroglobulinemia developing in a patient with multiple sclerosis: coincidence or association? Mult Scler 2004;10:598-600.
[23]  Aessopos A, Farmakis D, Hatziliami A, Fragodimitri C, Karabatsos F, Joussef J, Mitilineou E, Diamanti-Kandaraki E, Meletis J, Karagiorga M. Cardiac status in well-treated patients with thalassemia major. Eur J Haematol 2004;73:359-66.
[24]  Farmakis D, Vesleme V, Papadogianni A, Tsaftaridis P, Kapralos P, Aessopos A. Aneurysmatic dilatation of ascending aorta in a patient with β-thalassemia and a Pseudoxanthoma Elasticum-like syndrome. Ann Hematol 2004;83:596-9.
[25]  Aessopos A, Farmakis D, Tsironi M, Deftereos S, Tassiopoulos S, Konstantopoulos K, Rombos J, Papalambros E. Hemodynamic assessment of splenomegaly in beta-thalassemia patients undergoing splenectomy. Ann Hematol 2004;83:775-8.
[26]  Aessopos A, Deftereos S, Farmakis D, Corovesis C, Tassiopoulos S, Tsironi M, Georgonikou D, Moisakis J. Cardiovascular adaptation to chronic anemia in the elderly: An echocardiographic study. Clin Invest Med 2004;27:265-73.
[27]  Tsironi M, Korovesis K, Farmakis D, Deftereos S, Aessopos A. Hypoparathyroidism and heart failure in thalassemic patients: A case report. Pediatr Endocrinol Rev 2004;2 Suppl 2:310-2.
[28]  Tsironi M, Deftereos S, Andriopoulos P, Farmakis D, Meletis J, Aessopos A. Reversal of heart failure in thalassaemia major by combined chelation therapy: A case report. Eur J Haematol 2005;74:84-5.
[29]  Pectasides D, Farmakis D, Nikolaou M, Kanakis I, Kostopoulou V, Papaconstantinou I, Karamanos NK, Economopoulos T, Raptis SA. Diagnostic value of bone remodeling markers in the diagnosis of bone metastases in patients with breast cancer. J Pharm Biomed Anal 2005;37:171-176.
[30]  Pectasides D, Farmakis D, Koumarianou A. The role of neoadjuvant chemotherapy in the treatment of advanced ovarian cancer. Oncology 2005;68:64-70.
[31]  Pectasides D, Pectasides M, Farmakis D, Kostopoulou V, Nikolaou M, Gaglia A, Koumpou M, Mylonakis N, Xiros N, Economopoulos T, Raptis SA. Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial. Ann Oncol 2005;16:294-9.
[32]  Farmakis D, Horeftaki P, Kavouklis M, Aessopos A. Visual loss associated with angioid streaks in sickle thalassemia. Haematologica 2005;90:ECR02.
[33]  Pectasides D, Fountzilas G, Aravantinos G, Kalofonos HP, Efstathiou E, Salamalekis E, Farmakis D, Skarlos D, Briasoulis E, Economopoulos T, Dimopoulos MA. Advanced stage mucinous epithelial ovarian cancer: The Hellenic Cooperative Oncology Group experience. Gynecol Oncol 2005;97:436-41.
[34]  Parissis JT, Farmakis D, Kremastinos DT. Anti-inflammatory effects of levosimendan in decompensated heart failure: Impact on weight loss and anemia. Am J Cardiol 2005;95:923-4.
[35]  Pectasides D, Nikolaou M, Farmakis D, Kanakis I, Gaglia A, Kountourakis P, Karamanos NK, Economopoulos T, Raptis SA. Clinical value of bone remodeling markers in patients with bone metastases treated with zoledronic acid. Anticancer Res 2005;25:1457-63.
[36]  Aessopos A, Farmakis D, Deftereos S, Tsironi M, Polonifi A, Moyssakis I, Diamanti-Kandaraki E, Papalambros E. Cardiovascular effects of splenomegaly and splenectomy in B-thalassemia. Ann Hematol 2005; 84:353-7.
[37]  Aessopos A, Farmakis D, Deftereos S, Tsironi M, Tassiopoulos S, Moyssakis J, Karagiorga M. Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. Chest 2005;127:1523-30.
[38]  Grapsa A, Farmakis D, Variami E, Polonifi A, Diamanti-Kandaraki E, Papalambros E, Aroni K, Aessopos A. Hereditary hemorrhagic telangiectasia associated with vitiligo, autoimmune thyroiditis, iridocyclitis and a myelodysplastic syndrome. Clin Exper Dermatol 2005;30:448-50.
[39]  Parissis JT, Panou F, Farmakis D, Adamopoulos S, Filippatos G, Paraskevaidis I, Venetsanou K, Lekakis J, Kremastinos DT. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am J Cardiol 2005;96:423-6.
[40]  Farmakis D, Polymeropoulos E, Polonifi A, Deftereos S, Giakoumi X, Floudas H, Grapsa A, Aessopos A. Myelodysplastic syndrome associated with multiple autoimmune disorders. Clin Rheumatol 2005;24:428-30.
[41]  Tsironi M, Polonifi K, Deftereos S, Farmakis D, Andriopoulos P, Moyssakis I, Aessopos A. Transfusional hemosiderosis and combined chelation therapy in sickle thalassemia. Eur J Haematol 2005;75:355-358.
[42]  Farmakis D, Pectasides M, Pectasides D. Recent advances in conventional-dose salvage chemotherapy in patients with cisplatin-resistant or refractory testicular germ cell tumors. Eur Urol 2005;48:400-7.
[43]  Parissis JT, Filippatos G, Farmakis D, Adamopoulos S, Paraskevaidis I, Kremastinos DT. Levosimendan for the treatment of acute heart failure syndromes. Expert Opin Pharmacother 2005;6:2741-51.
[44]  Aessopos A, Farmakis D. Pulmonary hypertension in β-thalassemia. Ann N Y Acad Sci 2005;1054:342-9.
[45]  Tassiopoulos S, Deftereos S, Konstantopoulos K, Farmakis D, Tsironi M, Kyriakidis M, Aessopos A. Does heterozygous beta-thalassemia confer a protection against coronary disease? Ann N Y Acad Sci 2005;1054:467-70.
[46]  Pectasides D, Fountzilas G, Aravantinos G, Kalofonos C, Efstathiou H, Farmakis D, Skarlos D, Pavlidis N, Economopoulos T, Dimopoulos MA. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol 2006;102:285-91.
[47]  Farmakis D, Polonifi A, Deftereos S, Tsironi M, Papaioannou I, Aessopos A. Aortic valve replacement in a patient with thalassemia intermedia. Ann Thorac Surg 2006;81:737-9.
[48]  Aessopos A, Kati M, Tsironi M, Polonifi E, Farmakis D. Exchange blood transfusions for the treatment of leg ulcerations in thalassemia intermedia. Haematologica 2006;91:ECR11
[49]  Aessopos A, Tassiopoulos S, Farmakis D, Moyssakis I, Kati M, Polonifi K, Tsironi M. Extramedullary hematopoiesis-related pleural effusion: the case of beta-thalassemia. Ann Thorac Surg 2006;81:2037-43.
[50]  Adamopoulos S, Parissis JT, Iliodromitis EK, Paraskevaidis I, Tsiapras D, Farmakis D, Karatzas D, Gheorghiade M, Filippatos GS, Kremastinos DT. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol 2006;98:102-6.
[51]  Parissis JT, Farmakis D, Kremastinos DT. Levosimendan therapy in decompensated chronic heart failure: Favourable haemodynamic and neurohormonal effects but for how long? Eur J Heart Fail 2006;8:215.
[52]  Karavidas AI, Raisakis KG, Parissis JT, Tsekoura DK, Adamopoulos S, Korres DA, Farmakis D, Zacharoulis A, Fotiadis I, Matsakas E, Zacharoulis A. Functional electrical stimulation improves endothelial function and reduces peripheral immune responses in patients with chronic heart failure. Eur J Cardiovasc Prev Rehabil 2006;13:592-7.
[53]  Pectasides D, Farmakis D, Pectasides M. The management of stage I nonseminomatous testicular germ cell tumors. Oncology 2006;71:151-8.
[54]  Parissis JT, Adamopoulos S, Farmakis D, Filippatos G, Paraskevaidis I, Panou F, Iliodromitis E, Kremastinos DT. Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure. Heart 2006;92:1768-72.
[55]  Tsironi M, Korovesis K, Farmakis D, Deftereos S, Aessopos A. Hypocalcemic heart failure in thalassemia patient. Int J Hematol 2006;83:314-7.
[56]  Kati M, Tsironi M, Meletis I, Farmakis D, Giakoumis A, Aessopos A. Intervertebral disc calcification in a sickle cell thalassemia patient. Ann Hematol 2006;85:875-7.
[57]  Paraskevaidis IA, Vartela V, Tsiapras D, Iliodromitis EK, Parissis J, Farmakis D, Kremastinos DT. Tissue Doppler imaging analysis at pre-cardioversion time predicts recurrent atrial fibrillation: a 12-month follow-up study. J Cardiovasc Electrophysiol 2006;17:1005-10.
[58]  Parissis JT, Paraskevaidis I, Bistola V, Farmakis D, Panou F, Kourea K, Nikolaou M, Filippatos G, Kremastinos D. Effects of levosimendan on right ventricular function in patients with advanced heart failure. Am J Cardiol 2006;98:1489-92.
[59]  Aessopos A, Farmakis D, Tsironi M, Diamanti-Kandarakis E, Matzourani M, Fragodimiri C, Hatziliami A, Karagiorga M. Endothelial function and arterial stiffness in sickle-thalassemia patients. Atherosclerosis 2007;191:427-32.
[60]  Aessopos A, Farmakis D, Polonifi A, Tsironi M, Fragodimitri C, Hatziliami A, Karagiorga M, Diamanti-Kandarakis E. Plasma B-type natriuretic peptide concentration in beta-thalassemia patients. Eur J Heart Fail 2007;9:537-41.
[61]  Parissis JT, Farmakis D, Nieminen M. Classical inotropes and new cardiac enhancers. Heart Fail Rev 2007;12:149-56.
[62]  Paraskevaidis IA, Kyrzopoulos S, Tsiapras D, Iliodromitis EK, Parissis J, Farmakis D, Kremastinos DT. The role of left ventricular long axis contraction in patients with asymptomatic non-ischemic mitral valve regurgitation and normal systolic function. Int J Cardiol 2008;124:64-71.
[63]  Paraskevaidis I, Farmakis D, Parissis JT, Dodouras T, Filippatos G, Tsiapras D, Kremastinos DT. Carvedilol improves left atrial and left ventricular function and reserve in dilated cardiomyopathy after 1 year of treatment. J Card Fail 2007;13:108-13.
[64]  Parissis JT, Farmakis D, Bistola V, Adamopoulos S, Kremastinos DT.Levosimendan for the treatment of acute heart failure syndromes: time to identify subpopulations of responding patients. Am J Cardiol 2007;99:146-7.
[65]  Parissis JT, Papadopoulos C, Nikolaou M, Bistola V, Farmakis D, Paraskevaidis I, Filippatos G, Kremastinos D. Effects of levosimendan on quality of life and emotional stress in advanced heart failure patients. Cardiovasc Drugs Ther 2007;21:263-8.
[66]  Aessopos A, Kati M, Farmakis D, Polonifi E, Deftereos S, Tsironi M. Intensive chelation therapy in beta-thalassemia and possible adverse cardiac effects of desferrioxamine. Int J Hematol 2007;86:212-5.
[67]  Paraskevaidis IA, Kyrzopoulos S, Farmakis D, Parissis J, Tsiapras D, Iliodromitis EK, Kremastinos DT. Ventricular long-axis contraction as an earlier predictor of outcome in asymptomatic aortic regurgitation. Am J Cardiol 2007;100:1677-82.
[68]  Andreadou I, Iliodromitis EK, Koufaki M, Farmakis D, Tsotinis A, Kremastinos DT. Alternative pharmacological interventions that limit myocardial infarction. Curr Med Chem 2008;15:3204-13.
[69]  Farmakis D, Filippatos G, Tubaro M, Peacock WF, Disomma S, Mueller C, Kremastinos DT, Maisel AS. Natriuretic peptides in acute coronary syndromes: prognostic value and clinical implications. Congest Heart Fail 2008;14:25-9.
[70]  Farmakis D, Filippatos G, Kremastinos DT, Gheorghiade M. Vasopressin and vasopressin antagonists in heart failure and hyponatremia. Curr Heart Fail Rep 2008;5:91-6.
[71]  Karavidas A, Parissis J, Arapi S, Farmakis D, Korres D, Nikolaou M, Fotiadis J, Potamitis N, Driva X, Paraskevaidis I, Matsakas E, Filippatos G, Kremastinos DT. Effects of functional electrical stimulation on quality of life and emotional stress in patients with chronic heart failure secondary to ischaemic or idiopathic dilated cardiomyopathy: a randomised, placebo-controlled trial. Eur J Heart Fail 2008;10:709-13.
[72]  Kourea K, Parissis JT, Farmakis D, Paraskevaidis I, Panou F, Filippatos G, Kremastinos DT. Effects of darbepoetin-alpha on quality of life and emotional stress in anemic patients with chronic heart failure. Eur J Cardiovasc Prev Rehabil 2008;15:365-9.
[73]  Karavidas A, Lazaros G, Matsakas E, Farmakis D, Parissis J, Paraskevaidis IA, Michailidis C, Avramidis D, Zacharoulis A, Arapi S, Kaoukis A, Zacharoulis A. Clinical value of B-type natriuretic peptide for the assessment of left ventricular filling pressures in patients with systolic heart failure and inconclusive tissue Doppler indexes. Heart Vessels 2008;23:181-6.
[74]  Parissis JT, Kourea K, Panou F, Farmakis D, Paraskevaidis I, Ikonomidis I, Filippatos G, Kremastinos DT. Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am Heart J 2008;155:751.e1-7.
[75]  Farmakis D, Filippatos G, Lainscak M, Parissis JT, Anker SD, Kremastinos DT. Anticoagulants, antiplatelets, and statins in heart failure. Cardiol Clin 2008;26:49-58.
[76]  Aessopos A, Floudas CS, Kati M, Tsironi M, Giakoumi X, Livir-Rallatos C, Farmakis D. Loss of vision associated with angioid streaks in beta-thalassemia intermedia. Int J Hematol 2008;87:35-8.
[77]  Parissis JT, Karavidas A, Bistola V, Arapi S, Paraskevaidis IA, Farmakis D, Korres D, Filippatos G, Matsakas E, Kremastinos DT. Effects of levosimendan on flow-mediated vasodilation and soluble adhesion molecules in patients with advanced chronic heart failure. Atherosclerosis 2008;197:278-82.
[78]  Iliodromitis EK, Koutelou M, Paraskevaidis IA, Theodorakos A, Farmakis D, Tsoutsanis J, Kremastinos DT. Treadmill exercise test with dual isotope scintigraphy documents the second window of preconditioning in humans. Atherosclerosis 2008;198:122-8.
[79]  Kourea K, Parissis JT, Farmakis D, Panou F, Paraskevaidis I, Venetsanou K, Filippatos G, Kremastinos DT. Effects of darbepoetin-alpha on plasma pro-inflammatory cytokines, anti-inflammatory cytokine interleukin-10 and soluble Fas/Fas ligand system in anemic patients with chronic heart failure. Atherosclerosis 2008;199:215-21.
[80]  Parissis JT, Nikolaou M, Farmakis D, Bistola V, Paraskevaidis IA, Adamopoulos S, Filippatos G, Kremastinos DT. Clinical and prognostic implications of self-rating depression scales and plasma B-type natriuretic peptide in hospitalised patients with chronic heart failure. Heart 2008;94:585-9.
[81]  Parissis JT, Nikolaou M, Farmakis D, Paraskevaidis IA, Bistola V, Venetsanou K, Katsaras D, Filippatos G, Kremastinos DT. Self-assessment of health status is associated with inflammatory activation and predicts long-term outcomes in chronic heart failure. Eur J Heart Fail 2009;11:163-9.
[82]  Aessopos A, Farmakis D, Trompoukis C, Tsironi M, Moyssakis I, Tsaftarides P, Karagiorga M. Cardiac involvement in sickle beta-thalassemia. Ann Hematol 2009;88:557-64.
[83]  Parissis JT, Nikolaou M, Birmpa D, Farmakis D, Paraskevaidis I, Bistola V, Katsoulas T, Filippatos G, Kremastinos DT. Clinical and prognostic value of Duke's Activity Status Index along with plasma B-type natriuretic peptide levels in chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2009;103:73-5.
[84]  Paraskevaidis IA, Panou F, Papadopoulos C, Farmakis D, Parissis J, Ikonomidis I, Rigopoulos A, Iliodromitis EK, Th Kremastinos D. Evaluation of left atrial longitudinal function in patients with hypertrophic cardiomyopathy: a tissue Doppler imaging and two-dimensional strain study. Heart 2009;95:483-9.
[85]  Iliodromitis EK, Paraskevaidis IA, Fountoulaki K, Farmakis D, Andreadou I, Antoniadis A, Ikonomidis I, Leftheriotis D, Kremastinos DT. Staccato reperfusion prevents reperfusion injury in patients undergoing coronary angioplasty: a 1-year follow-up pilot study. Atherosclerosis 2009;204:497-502.
[86]  Gritsopoulos G, Iliodromitis EK, Zoga A, Farmakis D, Demerouti E, Papalois A, Paraskevaidis IA, Kremastinos DT. Remote postconditioning is more potent than classic postconditioning in reducing the infarct size in anesthetized rabbits. Cardiovasc Drugs Ther 2009;23:193-8.
[87]  Farmakis D, Filippatos G, Parissis J, Kremastinos DT, Gheorghiade M. Hyponatremia in heart failure. Heart Fail Rev 2009;14:59-63.
[88]  Andreadou I, Iliodromitis EK, Farmakis D, Kremastinos DT. To prevent, protect and save the ischemic heart: antioxidants revisited. Expert Opin Ther Targets 2009;13:945-56.
[89]  Paraskevaidis IA, Farmakis D, Papadopoulos C, Ikonomidis I, Parissis J, Rigopoulos A, Iliodromitis EK, Kremastinos DT. Two-dimensional strain analysis in patients with hypertrophic cardiomyopathy and normal systolic function: A twelve-month follow-up study. Αm Heart J 2009;158:444-50.
[90]  Parissis JT, Farmakis D, Nikolaou M, Birmpa D, Bistola V, Paraskevaidis I, Ikonomidis I, Gaitani S, Venetsanou K, Filippatos G, Kremastinos DT. Plasma B-type natriuretic peptide and anti-inflammatory cytokine interleukin-10 levels predict adverse clinical outcome in chronic heart failure patients with depressive symptoms: a 1-year follow-up study. Eur J Heart Fail 2009;11:967-72.
[91]  Aessopos A, Tsironi M, Andreopoulos A, Farmakis D. Cardiac status in thalassemia intermedia. Hemoglobin 2009;33 Suppl 1:S170-6.
[92]  Aessopos A, Farmakis D, Andreopoulos A, Tsironi M. Assessment and treatment of cardiac iron overload in thalassemia. Hemoglobin 2009;33 Suppl 1:S87-92.
[93]  Farmakis D, Parissis J, Kremastinos DT. The prognostic role of echocardiographic indices in chronic heart failure: Right ventricle revisited. Eur J Heart Fail 2009;11:1220.
[94]  Iliodromitis EK, Andreadou I, Prokovas E, Zoga A, Farmakis D, Fotopoulou T, Ioannidis K, Paraskevaidis IA, Kremastinos DT. Simvastatin in contrast to postconditioning reduces infarct size in hyperlipidemic rabbits: possible role of oxidative/nitrosative stress attenuation. Basic Res Cardiol 2010;105:193-203.
[95]  Kremastinos DT, Farmakis D, Anastasiou-Nana M. Drug-eluting stents: where are we today? Hellenic J Cardiol 2010;51:287-9.
[96]  Kremastinos DT, Farmakis D, Aessopos A, Hahalis G, Hamodraka E, Tsiapras D, Keren A. Beta-thalassemia cardiomyopathy: history, present considerations, and future perspectives. Circ Heart Fail 2010;3:451-8.
[97]  Farmakis D, Parissis JT, Bistola V, Paraskevaidis IA, Iliodromitis EK, Filippatos G, Kremastinos DT. Plasma B-type natriuretic peptide reduction predicts long-term response to levosimendan therapy in acutely decompensated chronic heart failure. Int J Cardiol 2010;139:75-9.
[98]  Ikonomidis I, Iliodromitis EK, Tzortzis S, Antoniadis A, Paraskevaidis I, Andreadou I, Fountoulaki K, Farmakis D, Kremastinos DT, Anastasiou-Nana M. Staccato reperfusion improves myocardial microcirculatory function and long-term left ventricular remodelling: a randomised contrast echocardiography study. Heart 2010;96:1898-903.
[99]  Parissis JT, Ikonomidis I, Rafouli-Stergiou P, Mebazaa A, Delgado J, Farmakis D, Vilas-Boas F, Paraskevaidis I, Anastasiou-Nana M, Follath F. Clinical characteristics and predictors of in-hospital mortality in acute heart failure with preserved left ventricular ejection fraction. Am J Cardiol 2011;107:79-84.
[100]  Iliodromitis EK, Farmakis D, Kremastinos DT. Biomarkers of myocardial injury as surrogate end-points for remote ischemic conditioning trials. Int J Cardiol 2011 [Epub ahead of print]
[101]  Farmakis D, Filippatos G. Istaroxime: Is the Remedy Better than the Disease?: Editorial to: "Chronic Istaroxine Improves Cardiac Function and Heart Rate Variability in Cardiomyopathic Hamsters" by Pietro Lo Giudice et al. Cardiovasc Drugs Ther 2011;25:115-7.
[102]  Farmakis D, Aessopos A. Pulmonary hypertension associated with hemoglobinopathies: Prevalent but yet overlooked. Circulation 2011;123:1227-32.
[103]  Farmakis D, Aessopos A. Prevention of microalbuminuria in diabetic patients with olmesartan: The J-curve revisited. N Engl J Med 2011;364:2260-3 (letter to the Editor).
[104]  Farmakis D, Filippatos G. Cardiorenal-anemia syndrome-definition, epidemiology and management: The Cardiologist's view. Hippokratia. 2011 (in press).
[105]  Kremastinos DT, Farmakis D. Iron overload cardiomyopathy in clinical practice. Circulation 2001 (in press).

Publications: Conferences/Workshops/Symposiums

[1]  The management of the cardiac complications of thalassaemia major. In: Guidelines for the clinical management of thalassaemia. Thalassaemia International Federation, April 2000: 35-40.
[2]  Il trattamento delle complicanze cardiache nella thalassemia major. In: Linea guida per il trattamento clinico della thalassemia. Idelson-Gnocchi, 2003: 45-52.
[3]  Aessopos Α, Farmakis D. Sickle Cell Disease: Introducing a distinct elastic tissue defect associated with inherited hemolytic syndromes. In: Plasmar RL (ed). Focus on sickle cell research. New York: Nova Biomedical Books, 2004: 157-79.
[4]  The management of the cardiac complications of thalassaemia major. In: Guidelines for the clinical management of thalassaemia, 2nd Edition. Thalassaemia International Federation, December 2007: 83-91.
[5]  The management of the cardiac complications of thalassaemia major. In: Guidelines for the clinical management of thalassaemia, 2nd Revised Edition. Thalassaemia International Federation, November 2008: 83-91.
[6]  Farmakis D, Aessopos A. Pulmonary hypertension: An emerging risk in hemoglobin disorder. Proceedings of the 12th International Conference on Thalassemia and the Hemoglobinopathies, 2011 (in press).
[7]  Aessopos A, Farmakis D, Berdoukas V. Cardiac failure in beta-thalassemia: Diagnosis, prevention and management. Proceedings of the 12th International Conference on Thalassemia and the Hemoglobinopathies, 2011 (in press).